Back to Search Start Over

Cystic fibrosis newborn screening (CF-NBS) start-up in Flanders (Belgium): report of first evaluation after 3 years

Authors :
Proesmans, Marijke
Régal, Luc
Eyskens, Francois
Roosens, L.
Marcélis, Lionel
Seneca, Sara
Storm, Katrien
Colaert, Karen
De Wachter, Elke
Growth and Development
Pediatrics
Medical Genetics
Clinical sciences
Reproduction and Genetics
Physiotherapy, Human Physiology and Anatomy
Publication Year :
2022
Publisher :
Elsevier, 2022.

Abstract

In January 2019, CF-NBS was started in Flanders (Belgium) involving 2 screenings labs using an IRT-DNA algorithm with a limited CFTR mutation panel and an IRT/IRT failsafe. Diagnosis is confirmed by sweat chloride (SCl) and CFTR mutation analysis. Methods: IRT was measured in dried blood spots (DBS) collected 72–96 hours after birth. If IRT was above the P99 cut-off, 12 CFTR mutations were searched for. Screen positive newborns (IRT>P99 and 1 or 2 mutations) were referred to a CF centre for quantitative pilocarpine iontophoresis (QPI). For IRT >P99.9 with negative mutation screening, a failsafe is provided with repeat IRT before day 21 (IRT-D21). For meconium ileus (MI), CF diagnostics are done irrespective of NBS result. CF centres provided feedback to the screening labs after diagnostic assessment. Results: In 2019 and 2020 (analysis of 2021 ongoing), 125,732 newborns were screened (coverage 99.9%). Sixty-eight (0.056%) had raised IRT plus at least 1 mutation. Three babies were screen +ve from the failsafe arm (IRTIRT) and 5 were sent for a QPI after ultra-high IRT, no mutation but missing the repeat IRT-D2. This resulted in 76 referrals for QPI. CF was confirmed in 24/76 babies (23/68 and in 1/5 newborn after the failsafe net without repeat IRT-D21; 43 babies were carriers, 3 were CRMS/CFSPID (CF metabolic syndrome/CF screen positive inconclusive diagnosis), 6 no CF/ no carrier. Median age at initial visit in the CF centre was 20 days and 23 days at diagnosis. CF centres reported no missed cases so far. Only 1 baby with MI had a negative CF-NBS, however this was not considered as false negative as per protocol. Based on these results, sensitivity was 100%, PPV 0.31 (calculated without CFSPID), and CF/CFSPID ratio was 8. Discussion: Performance of the program has been in agreement with ECFS standards. By June 2022, results will be extended to 3 years of screening. Based on current results, the IRT cut-off will be adapted to P99.2 to further improve the PPV.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.od......3848..3e0870c5034bff572df7c8070fdb37be